Eighteen million people worldwide suffer from rheumatoid arthritis (RA), a chronic autoimmune disease that attacks joint linings, causing swelling, inflammation, and damage to the affected area. As of now, RA cannot be cured, but disease-modifying antirheumatic drugs (DMARDs) or nonsteroidal anti-inflammatory drugs (NSAIDs) are used to limit symptoms. However, DMARDs increase the risk of infection by suppressing the immune system, while NSAIDs should only be used in the short term. In most cases, RA is found in joints; however, in some rare cases, it can spread to other parts of the body. When inflammation occurs, the body responds by releasing high levels of nuclear factor-kappa B (NF-kB), a group of proteins that promotes the expression of proinflammatory cytokines and chemokines. Our project aims to reduce the body’s inflammation response to RA by developing a response mechanism utilizing NF-kB. This design engineers Lactobacillus to produce curcumin, the anti-inflammatory molecule from the plant Curcuma longa, to significantly reduce the inflammatory response. By pairing the production of curcumin with the NF-kB-inducible promoter JTi2, our design becomes a self-regulating machine. Our goal is to create an automatic regulator and responder to abnormal levels of inflammation in the body, serving as a long-term treatment for those suffering from RA and possibly other autoimmune disorders.